Showing results (391-400 of 413) with videos related to
Sort By:
Pageof 42
Breast Cancer Research and Treatment|June 14, 2021
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancerHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.The Journal of Pathology|April 16, 2019
Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesiclesMaren Voglstaetter, Andreas R Thomsen, Jerome Nouvel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.Nature|July 28, 2021
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccineValerie Oberhardt, Hendrik Luxenburger, Janine Kemming, et al.Clinical Lymphoma, Myeloma & Leukemia|March 8, 2018
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI SubtrialSébastien Rinaldetti, Markus Pfirrmann, Kirsi Manz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Pageof 42